标题：Harmful effect of ER beta on BCRP-mediated drug resistance and cell proliferation in ER alpha/PR-negative breast cancer
作者：Li, Weiwei;Jia, Ming;Qin, Xiaomin;Hu, Jing;Zhang, Xiaofang;Zhou, Gengyin
作者机构：Department of Pathology and Pathophysiology, Shandong University School of Medicine, China;Department of Pathology and Pathophys
通讯作者地址：[Zhou, GY]Shandong Univ, Sch Med, Dept Pathol & Pathophysiol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
来源：The FEBS journal
关键词：BCRP;cell proliferation;E2;ERE;ERa/ PR-negative breast cancer;ERb;TAM
摘要：The role of estrogen receptor (ER) in breast cancer is still under investigation. Various studies have provided evidence that ER behaves as a tumor suppressor in breast cancer, whereas some studies of estrogen receptor (ER) negative breast cancer reported a positive correlation between high ER expression and poor prognostic phenotypes, such as induced proliferation, invasion and metastasis. In the present immunohistochemistry study of 99 ER/progesterone receptor (PR)-negative breast cancer samples, nuclear expression of ER was positively associated with membranous expression of breast cancer resistance protein (BCRP), Ki67 (proliferation marker) and tumor size. Moreover, both endogenous and exogenous ER upregulated BCRP expression which induced BCRP-mediated drug resistance and enhanced proliferation of ER-/PR- breast cancer cells in the presence of 17-estradiol, whereas these effects were reversed by additional use of tamoxifen (TAM). In addition, the regulation of BCRP via specific binding between ER and estrogen response element (ERE) was demonstrated in an electrophoretic mobility shift assay. Overall, our findings manifest that ER might act as a tumor promoter of cell proliferation and BCRP-mediated drug resistance in ER-/PR- breast cancer. TAM routinely used for patients with ER+/PR+, ER+/PR- and ER-/PR+ breast cancer might also be effective in ER-/PR- but ER+ breast cancer. Therefore, the detection of ER in clinic is valuable and should not be neglected in breast cancer, especially for the ER-/PR- phenotype.